Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Rare Diseases

Small Cell Lung Carcinoma

Melanoma

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Small Cell Lung Cancer

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Immunomodulating Agents

Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.

Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.

Patients with stage IV malignant melanoma treated with Immunotherapy with or without targeted therapy.

Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy.

Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.

Plasma sample collection

Shani Raveh Shoval, Ph.D.

Davika Das, MD

Yanyan Lou, MD

Jose Lutzky, MD

Ernesto Bustinza, MD

Anthony Magliocco, MD

So Hyeon Park

Marina Messinger

Marina Messinger, MD

William Fusselman, MD

Adam Berger, MD

Igor Puzanov, MD

Noam VanderWalde, MD

Ari VanderWalde, MD

Anita Sabichi, MD

Sunil Patel, MD

Ina Koch, PhD

Marc Schneider, PhD

Petros Christopoulos, MD

Mahmud Abu-Amana, MD

Gil Bar-Sela, Prof.

Kamel Mahmid, MD

Olga Vornicova, MD

Tatiana Charkovsky, MD

Moshe Schaffer, MD

Raya Leibowitz-Amit, MD

Nirit Yarom, MD

Tatiana Nisimov, MD

Svetlana Kovel, MD

Adi Rasco, MD

Alona Zer, MD

Mira Wollner, MD

Talia Shentzer, MD

Michal Lotem, Prof.

Hovav Hovav Nechushtan, Prof.

Jonathan Cohen, MD

Yakir Rottenberg, MD

Avner Mordechay, MD

Maya Gottfried, MD

Natalie Maimon-Rabinovich, MD

Moshe Mishaly, MD

Mor Moskovitz, MD

Hendler Daniel, MD

Rivka Katsenelson, MD

Elizabeta Dudnik, MD

Ronnie Shapira, MD

Jair Bar, MD

Amir Onn, MD

Sameh Daher, MD

Akram Saad, MD

Shirley Grinberg, MD

Ronen Shtoff, MD

Smadar Bauer, MD

Tamar Beller, MD

David Vicente, MD

Gillian Price, MD

Tom Geldart, MD

Andrew Conn, MD

David Farrugia, MD

Alison Brewster, MD

Andreas Polychronis, MD

Anirban Chatterjee, MD

Adam Hassani, MD

Helen Cheley

Louise Medley, MD

Michal Lotem, MD

Abed Agbaria, MD

Ido Wolf, MD

Alexander Yakobson, MD

Tatiana Harkovsky, MD

Raya Leibowitz, MD

Antony Magliocco, MD

Adam Hassani

Ronnie Shapira Frommer, MD

William P Fusselman, MD

David Vecente, MD

This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.

The goal of this research study is to develop an algorithm that predicts the patient's treatment outcome.This algorithm will serve as a tool for physicians when making treatment decisions, specifically for stage IV NSCLC and malignant melanoma patients receiving anti-cancer treatments. The investigators also aim to identify the metabolic pathways that could lead to better therapeutic options. The patients will be given their treatment according to the institute's standard of care. The patients will provide two blood samples and clinical data will be collected from their medical records.

In the first part of the trial, the data obtained from the blood samples and the medical records of the patients will be used to develop the prediction algorithm, and in the second part of the trial, the algorithm will be validated by comparing the objective response rate of the patients to the theoretical response prediction of the algorithm.

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Collect Progression Free Survival (PFS) dates

ORR as defined by RECIST 1.1 or other validated method for ORR evaluation

Changes in Blood levels of proteins representing the Host response

OncoHost Ltd.

Spots Global Cancer Trial Database for stage iii malignant melanoma